Global Paroxysmal Choreoathetosis Market, By Movement Characterization (Dystonia, Choreic, Ballistic, Combination), Symptoms (Paroxysmal Kinesigenic Dyskinesia, Paroxysmal Non Kinesigenic Dyskinesia, Paroxysmal Exertion-Induced Dyskinesia, Paroxysmal Hypogenic Dyskinesia), Treatment (Drugs, Therapies), Diagnosis (Genetic Testing, Clinical Testing), End-Users (Hospitals, Home Healthcare, Ambulatory Surgical Centres, Neurology Centres, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Paroxysmal Choreoathetosis Market
The paroxysmal choreoathetosis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.30% in the above-mentioned research forecast period. The demand for paroxysmal choreoathetosis having massive investments in research and development is acting as the fator driving the paroxysmal choreoathetosis market growth.
Paroxysmal choreoathetosis is a disorder characterized by movement disorder occurring due to episodes of involuntary movements in limbs, facial and trunk muscles. This disorder being genetic may occur in several members of a genetically connected family or may occur only in a single member of the family. The gene responsible for the disorder was found to be associated with the epilepsy as well. Prior to occurrence of paroxysmal choreoathetosis episode, some patients experience muscle tightening or similar symptom, these involuntary movements may trigger dome attacks if the patient consumes caffeine, alcohol or is stressed. These paroxysmal choreoathetosis attacks may last for about 10 seconds to even an hour.
There is a rise in awareness and initiatives for easing the life of patients suffering from paroxysmal choreoathetosis which drives the global paroxysmal choreoathetosis market. Moreover, many support groups as National Institute for Neurological Disorder and Stroke are being instrumental in providing funds for research and clinical trials which will boost up the paroxysmal choreoathetosis market growth. Research studies funded by National Institute for Neurological Disorder and Stroke are focused on finding ways to treat and prevent this particular neurological disorder. A collaboration of three non-profit organizations for launch of the Seizure Action Plan Coalition which would educate people about seizure emergency rescue protocols and the importance of personalized seizure action plans are bound to and expand weight of client maintenance and subsequently boost the global paroxysmal choreoathetosis market. Eton pharmaceuticals in collaboration with Aucta Pharmaceuticals, Inc. is all set to acquire marketing rights in the U.S. for its novel product ET-105, this will motivate the global paroxysmal choreoathetosis market. Also, Arvelle Therapeutics has exclusive rights to develop as well as commercialize Cenobamate in Europe, later in 2020 the European Medicines Agency accepted its application for marketing authorization. Lyrica, a product of Pfizer Inc. lost its patent rights earlier in 2019 in the U.S. which may motivate drug manufacturers to initiate manufacturing of its generic form which will boost the global paroxysmal choreoathetosis market.
Paroxysmal choreoathetosis is a rare disease occurring amongst 1 in 150,000 individuals, also this disorder is easily misinterpreted as psychogenic or hysterical in nature which is a restraint for the paroxysmal choreoathetosis market. Need and scarcity of specialized monitoring systems makes the process of diagnosis expensive which possess a negative impact on global paroxysmal choreoathetosis market. Lack of awareness and similarity of this disease with epilepsy is the main reason behind its misinterpretation.
Carbamazepine drug therapy which is usually effective in eliminating paroxysmal choreoathetosis attacks is not useful for every patient, this loop can be seen as an opportunity to invest in R&D in this direction to help paroxysmal choreoathetosis market grow. Paroxysmal dyskinesia is of intermittent and transient nature, precludes the use of botulinum toxin injections as a therapy which could be a relatively affordable alternative for patients. Also a new therapy called zonisamide monotherapy is found to be more effective then phenytoin in paroxysmal choreoathetosis patients which would cause a stir in the paroxysmal choreoathetosis market. Takeda Pharmaceutical Company in collaboration with Ovid Therapeutics Inc. is initiating three clinical trials for rare cases of epilepsy which is an opportunity for the paroxysmal choreoathetosis market to grow.
Even after advancement of science, we don’t have the knowledge about origin of this particular disease, there is lack of clinical trials in the field which is still a challenge for the global paroxysmal choreoathetosis market. Lack of any particular treatment and therapy for its treatment is a threat for the paroxysmal choreoathetosis market.
This paroxysmal choreoathetosis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the paroxysmal choreoathetosis market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Paroxysmal Choreoathetosis Market Scope and Market Size
The paroxysmal choreoathetosis market is segmented on the basis of movement characterization, symptoms, treatment, diagnosis, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of movement characterization, the paroxysmal choreoathetosis market is segmented into dystonia, choreic, ballistic and combination.
- On the basis of symptoms, the paroxysmal choreoathetosis market is segmented into paroxysmal kinesigenic dyskinesia, paroxysmal non kinesigenic dyskinesia, paroxysmal exertion-induced dyskinesia and paroxysmal hypogenic dyskinesia.
- On the basis of treatment, the paroxysmal choreoathetosis market is segmented into drugs and therapies.
- On the basis of diagnosis, the paroxysmal choreoathetosis market is segmented into genetic testing and clinical testing.
- On the basis of end-users, the paroxysmal choreoathetosis market is segmented into hospitals, home healthcare, ambulatory surgical centres, neurology centres and others.
- On the basis of distribution channel, the paroxysmal choreoathetosis market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Global Paroxysmal Choreoathetosis Market Country Level Analysis
Global paroxysmal choreoathetosis market is analysed and market size information is provided by the country, movement characterization, symptoms, treatment, diagnosis, end-users and distribution channel as referenced above.
The countries covered in the paroxysmal choreoathetosis market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts for the largest market share due to the increased consumption of anticonvulsants for the treatment of paroxysmal choreoathetosis.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The paroxysmal choreoathetosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to paroxysmal choreoathetosis market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the paroxysmal choreoathetosis market in the growth period.
Competitive Landscape and Paroxysmal Choreoathetosis Market Share Analysis
The paroxysmal choreoathetosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to paroxysmal choreoathetosis market.
The major players covered in the paroxysmal choreoathetosis market are Eton Pharmaceuticals, Inc., UCB Pharma Ltd, Bausch Health Companies Inc., Pfizer, Inc., Johnson & Johnson, Eisai Co., Ltd, Sunovion Pharmaceuticals, Ltd., Cephalon Inc., Abbott, Novartis Pharmaceuticals Corporation, Shire Pharmaceuticals Group Plc, Nostrum Laboratories Inc., GlaxoSmithKline plc, NeuroPace Inc., LivaNova Plc., Medtronic, SK Life Science, Inc., GW Pharmaceutical plc, Takeda Pharmaceutical Company Limited, Glenmark, Neurelis, Inc. among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Neurelis Inc. has a pipeline product named NRL-3 that is being developed for non-invasive therapy to treat seizures that may lead to a life threatening seizure emergency situation. They also received orphan drug designation from FDA.
SKU-
